Combination therapy for advanced bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination for advanced bile duct or gallbladder cancer that has not responded to earlier treatments. It aims to see if the combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced bile duct or gallbladder cancer that has come back or spread.
- Your cancer cells have a protein called EGFR, which the test checks for.
- You have already tried at least one standard treatment for your cancer.
- You are generally well enough to do daily activities (ECOG 0 or 1).
- You have at least one tumor that can be measured on a scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This study tests a combination of four drugs—two immunotherapy drugs (iparomlimab and toripalimab), a targeted therapy (bevacizumab), and chemotherapy—as a first-line treatment for advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to see if this combination can shrink tumors and help patients live longer.
This study tests a new drug called becotatug vedotin, added to standard chemotherapy, for advanced bile duct cancer that has a specific protein called EGFR. The goal is to see if this combination helps shrink tumors or slow the cancer better than standard treatment alone.
This trial tests two immunotherapy drugs for people with advanced bile duct or gallbladder cancer that has EGFR protein and has not responded to earlier treatment. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a new combination of two drugs for people with advanced head and neck cancer who cannot take standard platinum chemotherapy. The goal is to see if this treatment can help control the cancer and improve outcomes.
This trial tests a new combination of two drugs for advanced bile duct cancer (cholangiocarcinoma) that has not responded to previous treatment. The drugs work with your immune system to attack cancer cells, and may help slow the disease.
Hear when a new Biliary Tract Cancer (BTC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.